Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Up 64.4% in August

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNTGet Free Report) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 13,469 shares, a growth of 64.4% from the August 15th total of 8,194 shares. Based on an average trading volume of 45,610 shares, the short-interest ratio is currently 0.3 days. Currently, 1.1% of the company’s stock are sold short.

Regentis Biomaterials Stock Performance

RGNT opened at $1.80 on Thursday. The firm’s 50-day moving average price is $2.10 and its 200-day moving average price is $2.71. Regentis Biomaterials has a 52-week low of $1.23 and a 52-week high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNTGet Free Report) last released its earnings results on Friday, September 11th. The company reported ($0.22) EPS for the quarter.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNTFree Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent filing with the SEC.

About Regentis Biomaterials

(Get Free Report)

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.

See Also

Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.